Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution

doi:10.4330/wjc.v17.i2.103845

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=0

Feb 26, 2025 (publication date) through Feb 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Cardiol. Feb 26, 2025; 17(2): 103845
Published online Feb 26, 2025. doi: 10.4330/wjc.v17.i2.103845

Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution

Li-You Lian, Chen-Xiao Huang, Qin-Fen Chen, Xiao-Dong Zhou

Li-You Lian, Chen-Xiao Huang, Xiao-Dong Zhou, MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China

Qin-Fen Chen, Department of Physical Examination Medical Care Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China

Author contributions: Zhou XD project administration, funding acquisition, supervision, conceptualization; Lian LY writing-original draft, visualization; Huang CX and Chen QF writing-review & editing.

Supported by Wenzhou Science Technology Bureau Foundation, No. 2022Y0726.

Conflict-of-interest statement: Li-You Lian, Chen-Xiao Huang, Qin-Fen Chen and Xiao-Dong Zhou have nothing to disclose.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Xiao-Dong Zhou, MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, Zhejiang Province, China. zhouxiaodong@wmu.edu.cn

Received: December 3, 2024
Revised: January 16, 2025
Accepted: January 21, 2025
Published online: February 26, 2025
Processing time: 84 Days and 20.5 Hours

Core Tip

Core Tip: The coexistence of heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD), poses significant clinical challenges due to their intricate relationship and similar metabolic pathophysiology. Clinical management strategies for HFpEF and MASLD still faces challenges. Sodium-glucose cotransporter 2 inhibitors showing benefits in HFpEF or MASLD, while other drugs, such as glucagon-like peptide-1 receptor agonists and statins remains under investigation. A holistic, patient-centered approach combining metabolic and cardiovascular care is vital for improving HFpEF and MASLD outcomes in global metabolic health challenges.